Pharmacopeia to Present at the Rodman & Renshaw 8th Annual Healthcare Conference
31 Oktober 2006 - 1:30PM
PR Newswire (US)
PRINCETON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Pharmacopeia
(NASDAQ: PCOP), an innovator in the discovery and development of
novel small molecule therapeutics, today announced that Dr. Leslie
J. Browne, President and Chief Executive Officer, will deliver a
corporate presentation at the Rodman & Renshaw 8th Annual
Healthcare Conference. The conference will be held November 6 - 8,
2006, at The New York Palace Hotel in New York City. Dr. Browne's
presentation will take place at 3:30 p.m. (local time) on Monday,
November 6. The presentation will include an overview of the
company's drug development pipeline, recent corporate
accomplishments and expected milestones. A live webcast and 90-day
archive of the presentation can be accessed at
http://www.pharmacopeia.com/. Pharmacopeia's most advanced internal
program is a dual-acting angiotensin and endothelin receptor
antagonist (DARA) for hypertension and diabetic nephropathy that is
currently in preclinical development. Pharmacopeia's internal
programs in advanced optimization are: JAK3 inhibitors
(immunomodulators for multiple potential indications, including
transplant rejection, psoriasis and rheumatoid arthritis); CCR1
antagonists (with potential in inflammatory diseases such as
rheumatoid arthritis and multiple sclerosis); adenosine A2A
antagonists (with potential in neurodegenerative diseases,
including Parkinson's and Alzheimer's); and avb3/avb5 inhibitors
(with potential to block angiogenesis in cancer and inflammation).
Pharmacopeia currently has eleven partnered compounds in
development with major pharmaceutical or biotechnology companies.
Five of these compounds (representing four partnered, therapeutic
programs) are currently in Phase I clinical trials for rheumatoid
arthritis, an allergy/asthma indication, chronic obstructive
pulmonary disease (COPD) and oncology. Six compounds are in
preclinical development. Pharmacopeia will receive milestone
payments for those programs that successfully advance through
clinical development and royalties on the sales of any compounds
that are commercialized. ABOUT PHARMACOPEIA Pharmacopeia is
committed to creating and delivering novel therapeutics to address
significant medical needs using proprietary technologies and
processes. The Company is advancing multiple internal programs
towards validation in clinical trials. Pharmacopeia's later stage
portfolio currently comprises multiple partnered programs that have
been advanced into clinical trials with further programs in
preclinical development. The Company also has several internal
programs - one in preclinical development and several in advanced
optimization - as well as multiple partnered programs in discovery
that are expected to drive the Company's clinical portfolio in the
future. Contact: Amy Sharpless Pharmacopeia (609) 452-3643 This
press release, and oral statements made with respect to information
contained in this press release, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
which express plan, anticipation, intent, goal, contingency or
future development and/or otherwise are not statements of
historical fact. These statements are based upon management's
current expectations and are subject to risks and uncertainties,
known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied
in such statements. These forward-looking statements include, but
are not limited to, statements about the successful implementation
of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop
its DARA program and file an IND with respect to the program,
Pharmacopeia's ability to successfully perform under its
collaborations with Cephalon and GlaxoSmithKline, Pharmacopeia's
ability to build its pipeline of novel drug candidates through its
own internally funded drug discovery programs, third party
collaborations and in-licensing, the continuation and funding level
of such continuation of Pharmacopeia's existing drug discovery
collaboration with N.V. Organon, Pharmacopeia's intentions
regarding the establishment of new drug discovery collaborations
with leading pharmaceutical and biotechnology organizations,
Pharmacopeia's ability to raise additional capital, Pharmacopeia's
expectations concerning the development priorities of its
collaborators, their ability to successfully develop compounds and
its receipt of milestones and royalties from the collaborations,
Pharmacopeia's anticipated operating results, financial condition,
liquidity and capital resources, Pharmacopeia's expectations
concerning the legal protections afforded by U.S. and international
patent law, Pharmacopeia's ability to pursue the development of new
compounds and other business matters without infringing the patent
rights of others, additional competition, and changes in economic
conditions. Further information about these and other relevant
risks and uncertainties may be found in Pharmacopeia's Reports on
Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Pharmacopeia urges you to carefully review and consider
the disclosures found in its filings which are available in the SEC
EDGAR database at http://www.sec.gov/ and from Pharmacopeia at
http://www.pharmacopeia.com/. All forward-looking statements in
this press release and oral statements made with respect to
information contained in this press release are qualified entirely
by the cautionary statements included in this press release and
such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by
such forward-looking statements. These forward-looking statements
speak only as of the date of this press release. Pharmacopeia
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise. DATASOURCE:
Pharmacopeia CONTACT: Amy Sharpless of Pharmacopeia,
+1-609-452-3643 or Web Site: http://www.pharmacopeia.com/
Copyright